A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).-MedSci.cn

A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).

Choueiri, TK; Apolo, AB; Powles, T; Escudier, B; Aren, OR; Shah, A

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (15):

科室
- - 订阅+
  - 更多科室
工具
服务